Cipla Bommasandra facility gets VAI classification from USFDA
Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the current Good Manufacturing Practices (cGMP) inspection at the Company’' manufacturing facility in Bommasandra, Bengaluru as Voluntary Action Indicated (VAI).
The inspection was conducted from 26th to 30th May, 2025. Initially, the company received one observation for the said facility.
Voluntary action indicated means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
Read also: USFDA issues one observation for Cipla Bommasandra facility
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. The company strengths lies in the respiratory, anti-retroviral, urology, cardiology, antiinfective and CNS segments. Cipla 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 74+ markets.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.